AzTrials
AzTrials

Non-small Cell Lung CancerPhase 3NCT03631706

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 3 study testing M7824 and Pembrolizumab in people with Non-small Cell Lung Cancer, run by EMD Serono Research & Development Institute, Inc. at 119 sites in 18 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Non-small Cell Lung Cancer
What is being tested?
M7824 and Pembrolizumab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
304 participants
Where
119 sitesin 18 countries
Study dates
1 Oct 2018to 25 Jun 2024
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically confirmed diagnosis of advanced NSCLC
  • Have not received prior systemic therapy treatment for their advanced/Stage four NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy to Grade less than or equal to 1. For radiation toxicity or prior major surgeries, participants should have recovered from side effects and/or complications
  • Have measurable disease based on RECIST 1.1
  • Have a life expectancy of at least 3 months
  • Availability of tumor tissue (less than 6 months old) before the first dose is mandatory to determine PD-L1 expression level prior to enrollment
  • PD-L1 high status as determined by central testing
  • Other protocol defined inclusion criteria could apply

Who cannot join

  • Participants with nonsquamous NSCLC histologies whose tumor harbors any of the following molecular alterations and targeted therapy is locally approved: epidermal growth factor receptor (EGFR) sensitizing (activating) mutation, anaplastic lymphoma kinase (ALK) translocation, ROS1 rearrangement, or BRAF V600E mutation
  • Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy of greater than 30 units of gray (Gy) within 6 months prior to the first dose of study
  • Known severe hypersensitivity to investigational products (M7824 or pembrolizumab), or any components in their formulations
  • Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years
  • Other protocol defined exclusion criteria could apply

Trial locations and contacts

119 sites in 18 countries.

119 sites in 18 countries

United States25 sites

  • Texas Oncology - Bedford

    Bedford, Texas, 76022

  • The University of Chicago Medical Center

    Chicago, Illinois, 60637

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Rocky Mountain Cancer Centers - Colorado Springs, N. Nevada

    Colorado Springs, Colorado, 80907

  • Decatur Memorial Hospital - Clinical Research

    Decatur, Illinois, 62526

  • Henry Ford Medical Center

    Detroit, Michigan, 48202

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia, 22031

  • Oncology Specialties, PC; Clearview Cancer Institute

    Huntsville, Alabama, 35805

  • Cancer Specialists, LLC - Department of Clinical Research

    Jacksonville, Florida, 32256

  • Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC - Menorah Medical Center - Oncology Account

    Kansas City, Missouri, 64132

  • Baptist Health Lexington Oncology Associates

    Lexington, Kentucky, 40503

  • Southeast Nebraska Cancer Center

    Lincoln, Nebraska, 68510

  • Cedars Sinai Medical Center - Inflammatory Bowel Disease Center (Clinic

    Los Angeles, California, 90048

  • Norton Cancer Institute

    Louisville, Kentucky, 40202

  • SCRI - Tennessee Oncology

    Nashville, Tennessee, 37203

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

  • Eastern Connecticut Hematology/Oncology Assoc.

    Norwich, Connecticut, 06360

  • UC Irvine Medical Center

    Orange, California, 92868

  • The Valley Hospital - Luckow Pavilion

    Paramus, New Jersey, 07652

  • Woodlands Medical Specialists

    Pensacola, Florida, 32503

  • UPMC Cancer Center

    Pittsburgh, Pennsylvania, 15232

  • University of Rochester Medical Center

    Rochester, New York, 14642

  • Kaiser Permanente - Harbor City

    San Diego, California, 92120

  • Sansum Clinic - Santa Barbara

    Santa Barbara, California, 93105

  • Texas Oncology, P.A. - Sugarland

    Sugar Land, Texas, 77479

Other trials in United States

Spain10 sites

  • Hospital del Mar - Servicio de Oncologia

    Barcelona, 08003

  • Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica

    Barcelona, 08028

  • Hospital Universitari Vall d'Hebron - Dept of Oncology

    Barcelona, 08035

  • ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia

    L'Hospitalet de Llobregat, 08908

  • Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica

    Madrid, 28007

  • Hospital Universitario 12 de Octubre - Servicio de Oncologia

    Madrid, 28041

  • Hospital Regional Universitario de Malaga

    Málaga, 29010

  • Hospital Universitario Virgen Macarena - Servicio de Oncologia

    Seville, 41009

  • Hospital Universitario Virgen del Rocio - Servicio de Oncologia

    Seville, 41013

  • Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica

    Valencia, 46026

Other trials in Spain

Japan8 sites

  • National Cancer Center Hospital - Dept of Respiratory Medicine

    Chūōku, 104-0045

  • Saitama Medical University International Medical Center - Dept of Respiratory Medicine

    Hidaka-shi

  • Saitama Cancer Center

    Kitaadachigun, 362-0806

  • Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine

    Kōtoku, 135-8550

  • Kurume University Hospital

    Kurume-shi, 830-0011

  • Osaka Medical Center for Cancer and Cardiovascular Diseases

    Osaka, 541-8567

  • Kindai University Hospital

    Osakasayama-sh, 589-8511

  • NHO Hokkaido Cancer Center - Dept of Respiratory Medicine

    Sapporo, Hokkaido, 003-0804

Other trials in Japan

France7 sites

  • Hôpital Nord - AP-HM Marseille# - Service d'Oncologie Multidisciplinaire

    Bouches-du-Rhône, 13915

  • Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie

    Créteil, Val De Marne, 94010

  • Centre Léon Bérard

    Lyon, 69373

  • Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Maison du Ha

    Pessac, Gironde, 33604

  • CHU Rennes - Hopital Pontchaillou - service de pneumologie

    Rennes, 35033

  • ICO - Site René Gauducheau

    Saint-Herblain, 44805

  • CHU de Toulouse - Hôpital Larrey - Service de Pneumologie et Oncologie Pneumologique

    Toulouse, 31059

Other trials in France

Italy7 sites

  • Azienda Ospedaliera San Giuseppe Moscati - U.O Oncologia Medica

    Avellino, 83100

  • IRCCS Centro di Riferimento Oncologico - Oncologia Medica A

    Aviano, 33081

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Oncologia Medica

    Bologna, 40138

  • Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico - Unità Operativa di Oncologia

    Catania, 95123

  • Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario - Centro Oncologico

    Catanzaro, 88100

  • Fondazione IRCCS Istituto Nazionale dei Tumori - Medicina Oncologica I

    Milan, 20133

  • Università degli studi della Campania Luigi Vanvitelli - Dipartimento di Oncologia

    Naples, 80131

Other trials in Italy

South Korea7 sites

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, 28644

  • Gachon University Gil Medical Center

    Incheon, 21565

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620

  • Seoul National University Hospital

    Seoul, 03080

  • Severance Hospital, Yonsei University

    Seoul, 03722

  • Asan Medical Center

    Seoul, 05505

  • Samsung Medical Center

    Seoul, 06351

Other trials in South Korea

Argentina6 sites

  • Centro de Oncologia e Investigacion Buenos Aires

    Berazategui, B1880BBF

  • Instituto Medico Especializado Alexander Fleming

    Ciudad Autonoma Buenos Aires, C1426ANZ

  • Sanatorio Allende

    Córdoba, X5000JHQ

  • Instituto Medico Rio Cuarto

    Río Cuarto, 5800

  • Instituto de Oncología de Rosario

    Rosario, S2000KZE

  • Centro Medico San Roque S.R.L.

    San Miguel de Tucumán, 4000

Other trials in Argentina

Brazil6 sites

  • Hospital de Câncer de Barretos - Fundação Pio XII

    Barretos, 14784-400

  • CRIO - Centro Regional Integrado de Oncologia

    Fortaleza, 60336-045

  • Hospital São Lucas da PUCRS

    Porto Alegre, 90610-000

  • INCA - Instituto Nacional de Câncer

    Rio de Janeiro, 20230-230

  • NOB - Núcleo de Oncologia da Bahia

    Salvador, 40170-110

  • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia - Faculdade de Medicina do ABC

    Santo André, 09060-650

Other trials in Brazil

Germany6 sites

  • Vivantes Klinikum Am Urban - Haematologie und Onkologie

    Berlin, 10967

  • Asklepios Fachkliniken Muenchen-Gauting - Abteilung Internistische Onkologie

    Gauting, 82131

  • LungenClinic Grosshansdorf

    Großhansdorf, 22927

  • Medizinische Hochschule Hannover - Pneumologie

    Hanover, 30625

  • Universitaetsklinikum Schleswig- Holstein Campus Luebeck

    Lübeck, 23538

  • Universitaetsklinikum Regensburg - Klinik und Poliklinik fuer Innere Medizin II

    Regensburg

Other trials in Germany

Netherlands6 sites

  • Antoni van Leeuwenhoek Ziekenhuis

    Amsterdam, 1066 CX

  • VU Medisch Centrum

    Amsterdam, 1081 HV

  • Universitair Medisch Centrum Groningen (UMCG) - Parent

    Groningen, 9713 GZ

  • Maastricht University Medical Center - Dept of Medical Oncology

    Maastricht, 6202 AZ

  • Erasmus Medisch Centrum

    Rotterdam, 3015 CE

  • St. Elisabeth Ziekenhuis - Parent

    Tilburg, 5022 GC

Other trials in Netherlands

Ukraine6 sites

  • CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU - Ch of Oncology and MR

    Dnipro, 49102

  • CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU - Chair of Oncology

    Ivano-Frankivsk, 76018

  • Communal Non-profit Enterprise Regional Center of Oncology - Parent

    Kharkiv, 61070

  • Medical and Preventive Treatment Institution Volyn Regional Oncological Dispensary - Dept of Oncochemotherapy

    Lutsk, 43018

  • CCCH City Oncological Center SHEI Uzhgorod NU - Ch of R&O of Faculty of PGE&PUT

    Uzhhorod, 88000

  • Medical center "Oncolife"

    Zaporizhzhya, 69059

Other trials in Ukraine

Belgium4 sites

  • Universitair Ziekenhuis Brussel - Geriatrie

    Brussels, 1090

  • Jessa Ziekenhuis Hospital

    Hasselt, 3500

  • UZ Leuven

    Pellenberg, 3212

  • CHU Mont-Godinne

    Yvoir, 5530

Other trials in Belgium

Greece4 sites

  • 251 General Air Force Hospital

    Athens, 11525

  • General Hospital of Athens of Chest Disease "SOTIRIA"

    Athens, 11527

  • University General Hospital of Heraklion "PAGNI"

    Heraklion, 71110

  • General Hospital Papageorgiou-2nd Department of Dermatalogy

    Thessaloniki, 56429

Other trials in Greece

Taiwan4 sites

  • Taichung Veterans General Hospital

    Taichung, 40705

  • National Taiwan University Hospital

    Taipei, 100

  • Taipei Veterans General Hospital

    Taipei, 11217

  • Tri-Service General Hospital

    Taipei, 11490

Other trials in Taiwan

Turkey (Türkiye)4 sites

  • Adana Numune Training and Research Hospital - Cardiology Department

    Adana, 01370

  • Dr. Abdurrahman Yurtaslan Oncology Teaching and Research Hospital - Oncology Department

    Ankara, 06105

  • Trakya University Medical Faculty - Medical Oncology

    Edirne, 22030

  • Kocaeli University Research and Application Hospital

    Kocaeli, 41380

Other trials in Turkey (Türkiye)

Canada3 sites

  • Tom Baker Cancer Centre

    Alberta, T2N 4N2

  • Stronach Regional Cancer Centre - at Southlake

    Ontario, L3Y 2P9

  • Saint John Regional Hospital

    Saint John, New Brunswick, E2L 4L2

Other trials in Canada

China3 sites

  • Peking University Cancer Hospital

    Beijing, 100142

  • Guangdong General Hospital

    Guangzhou, 510080

  • Shanghai Cancer Hospital, Fudan University

    Shanghai, 200032

Other trials in China

Hong Kong3 sites

  • Princess Margaret Hospital

    Hong Kong, 00000

  • The University of Hong Kong

    Hong Kong

  • The Chinese University of Hong Kong - Emergency Medicine

    Shatin, 00000

Other trials in Hong Kong

About this study

Official title: An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer

The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. The Phase III adaptive design allows for the option to recruit up to 584 patients based on pre-specified rules.

Being tested
M7824, Pembrolizumab
Keywords
M7824, Pembrolizumab, PD-L1-tumor Expression, INTR@PID Lung 037, Bintrafusp alfa
Medical subject headings
Carcinoma, Non-Small-Cell Lung

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • M7824Drug

    Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.

  • PembrolizumabDrug

    Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.

Study groups in NCT03631706
Study groupRoleWhat they receive
M7824ExperimentalNot described
Receives: Drug: M7824
PembrolizumabActive comparatorNot described
Receives: Drug: Pembrolizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)

    Progression free survival was defined as the time from randomization of study intervention until the first documentation of disease progression (PD) or death due to any cause, whichever occurred first. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Measured: Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days

  2. Overall Survival (OS)

    Overall Survival was defined as the time from randomization of study intervention to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method.

    Measured: Time from randomization of study drug assessed approximately up to 843 days

Secondary outcomes (3)

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

    Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on treatment period. TEAEs included serious AEs and non-serious AEs. Treatment-related TEAEs: reasonably related to the study intervention.

    Measured: Time from first treatment assessed up to approximately 843 days

  2. Percentage of Participants With Unconfirmed Best Overall Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)

    Percentage of participants with unconfirmed best overall response that is at least one overall assessment of complete response (CR) or partial response (PR) reported here.

    Measured: Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days

  3. Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)

    DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DOR was determined according to RECIST v1.1 and assessed by IRC. Results were calculated based on Kaplan-Meier estimates.

    Measured: From first documented objective response to PD or death due to any cause, assessed approximately up to 746 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2018
  2. Study start1 Oct 2018
  3. Primary completion7 Jun 2021
  4. Study completion25 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
304 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03631706
Sponsor's protocol ID
MS200647_0037
Other IDs
2018-001517-32, 2018
Status last verified
Mar 2025
First submitted
9 Aug 2018
Last updated
8 Apr 2025
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

Publications

  • Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.

    PubMed 23886301

  • Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 Dec;18(12):1731-1742. doi: 10.1016/j.jtho.2023.08.018. Epub 2023 Aug 18.

    PubMed 37597750

  • Milenkovic-Grisic AM, Terranova N, Mould DR, Vugmeyster Y, Mrowiec T, Machl A, Girard P, Venkatakrishnan K, Khandelwal A. Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trials. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):143-153. doi: 10.1002/psp4.13068. Epub 2023 Dec 13.

    PubMed 38087967

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing M7824 and Pembrolizumab in people with Non-small Cell Lung Cancer, run by EMD Serono Research & Development Institute, Inc. at 119 sites in 18 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 119 sites in United States, Spain, Japan, France, Italy and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Jun 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC) (time frame: Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03631706, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in